Handelsman Y

ORCID: 0000-0001-7830-0247 · 1 paper in corpus

2019

Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.

Diabetes, obesity & metabolism ·doi:10.1111/dom.13594

AimsTo compare the efficacy and safety of an intensification strategy of early triple combination therapy with dapagliflozin (DAPA) plus saxagliptin (SAXA) to a dual therapy strategy with sitagliptin (SITA) in patients with type 2 diabetes …